BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 19904268)

  • 1. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study.
    Wilkowski R; Boeck S; Ostermaier S; Sauer R; Herbst M; Fietkau R; Flentje M; Miethe S; Boettcher HD; Scholten T; Bruns CJ; Rau HG; Hinke A; Heinemann V
    Br J Cancer; 2009 Dec; 101(11):1853-9. PubMed ID: 19904268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
    Mukherjee S; Hurt CN; Bridgewater J; Falk S; Cummins S; Wasan H; Crosby T; Jephcott C; Roy R; Radhakrishna G; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T
    Lancet Oncol; 2013 Apr; 14(4):317-26. PubMed ID: 23474363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients.
    Brunner TB; Sauer R; Fietkau R
    Radiat Oncol; 2011 Jul; 6():88. PubMed ID: 21794119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
    Landry J; Catalano PJ; Staley C; Harris W; Hoffman J; Talamonti M; Xu N; Cooper H; Benson AB
    J Surg Oncol; 2010 Jun; 101(7):587-92. PubMed ID: 20461765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.
    Chauffert B; Mornex F; Bonnetain F; Rougier P; Mariette C; Bouché O; Bosset JF; Aparicio T; Mineur L; Azzedine A; Hammel P; Butel J; Stremsdoerfer N; Maingon P; Bedenne L
    Ann Oncol; 2008 Sep; 19(9):1592-9. PubMed ID: 18467316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
    Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer.
    Kurt E; Kurt M; Kanat O; Cetintas SK; Aygun S; Palazoglu T; Ozkan L; Evrensel T; Kaya E; Manavoglu O
    Tumori; 2006; 92(6):481-6. PubMed ID: 17260487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma.
    Gu MF; Liu LZ; He LJ; Yuan WX; Zhang R; Luo GY; Xu GL; Zhang HM; Yan CX; Li JJ
    Int J Cancer; 2013 Jan; 132(1):215-23. PubMed ID: 22610788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline
    O'Reilly EM; Lee JW; Zalupski M; Capanu M; Park J; Golan T; Tahover E; Lowery MA; Chou JF; Sahai V; Brenner R; Kindler HL; Yu KH; Zervoudakis A; Vemuri S; Stadler ZK; Do RKG; Dhani N; Chen AP; Kelsen DP
    J Clin Oncol; 2020 May; 38(13):1378-1388. PubMed ID: 31976786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
    Kim JS; Lim JH; Kim JH; Im SA; Chie EK; Hwang JH; Kim TY; Bang YJ; Ha SW; Yoon YB
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):381-9. PubMed ID: 22806305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.
    Herman JM; Wild AT; Wang H; Tran PT; Chang KJ; Taylor GE; Donehower RC; Pawlik TM; Ziegler MA; Cai H; Savage DT; Canto MI; Klapman J; Reid T; Shah RJ; Hoffe SE; Rosemurgy A; Wolfgang CL; Laheru DA
    J Clin Oncol; 2013 Mar; 31(7):886-94. PubMed ID: 23341531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience.
    Gillmore R; Laurence V; Raouf S; Tobias J; Blackman G; Meyer T; Goodchild K; Collis C; Bridgewater J
    Clin Oncol (R Coll Radiol); 2010 Sep; 22(7):564-9. PubMed ID: 20605709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
    Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
    Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
    Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
    Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
    J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
    Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
    Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
    Reni M; Cereda S; Mazza E; Passoni P; Nicoletti R; Balzano G; Zerbi A; Arcidiacono PG; Staudacher C; Di Carlo V
    Am J Clin Oncol; 2008 Apr; 31(2):145-50. PubMed ID: 18391598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
    Middleton G; Silcocks P; Cox T; Valle J; Wadsley J; Propper D; Coxon F; Ross P; Madhusudan S; Roques T; Cunningham D; Falk S; Wadd N; Harrison M; Corrie P; Iveson T; Robinson A; McAdam K; Eatock M; Evans J; Archer C; Hickish T; Garcia-Alonso A; Nicolson M; Steward W; Anthoney A; Greenhalf W; Shaw V; Costello E; Naisbitt D; Rawcliffe C; Nanson G; Neoptolemos J
    Lancet Oncol; 2014 Jul; 15(8):829-40. PubMed ID: 24954781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
    Rakhra S; Strauss JB; Robertson J; McGinn CJ; Kim T; Huang J; Blake A; Helenowski I; Hayes JP; Mulcahy M; Small W
    J Gastrointest Cancer; 2016 Jun; 47(2):196-201. PubMed ID: 27112332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.